Skip to main content
. 2012 Dec 10;31(3):359–364. doi: 10.1200/JCO.2012.44.4711

Table 1.

Patient Characteristics (analyzed patients) of NSABP C-08

Characteristic mFF6 (n = 1,338)
mFF6+Bev (n =. 1,335)
Total (N = 2,673)
No. of Patients % No. of Patients % No. of Patients %
Age, years
    < 50 332 24.8 342 25.6 674 25.2
    50-59 447 33.4 435 32.6 882 33.0
    60-69 347 25.9 366 27.4 713 26.7
    ≥ 70 212 15.8 192 14.4 404 15.1
Sex
    Female 673 50.3 669 50.1 1,342 50.2
    Male 665 49.7 666 49.9 1,331 49.8
Race
    White 1,172 87.6 1,161 87 2,333 87.3
    Black 101 7.5 114 8.5 215 8
    Other 50 3.7 43 3.2 93 3.5
    Multiracial 2 0.1 1 0.1 3 0.1
    Unknown 13 1.0 16 1.2 29 1.1
ECOG performance status
    0 (fully active) 1,089 81.4 1,075 80.6 2,164 81.0
    1 (no strenuous activity) 249 18.6 259 19.4 508 19.0
Nodal stage
    N0 (node negative) 332 24.8 334 25.0 666 24.9
    N1 (1-3 positive nodes) 611 45.7 607 45.5 1,218 45.6
    N2 (≥ 4 positive nodes) 395 29.5 394 29.5 789 29.5

Abbreviations: ECOG, Eastern Cooperative Oncology Group; mFF6, modified fluorouracil, leucovorin, and oxaliplatin for 6 months; mFF6 + Bev, mFF6 for 6 months plus bevacizumab for 12 months; NSABP, National Surgical Adjuvant Breast and Bowel Project.